Why Balu Balakrishnan Sold 3,116 Shares of Power Integrations, Inc. (POWI)?; Profile of 6 Analysts Covering Synergy Pharmaceuticals Inc. (SGYP)

Among 8 analysts covering Synergy Pharmaceuticals (NASDAQ:SGYP), 6 have Buy rating, 1 Sell and 1 Hold. Therefore 75% are positive. Synergy Pharmaceuticals had 39 analyst reports since August 25, 2015 according to SRatingsIntel. The rating was maintained by Cantor Fitzgerald on Wednesday, September 27 with “Buy”. The stock of Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) has “Buy” rating given on Monday, January 8 by H.C. Wainwright. Citigroup downgraded Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) on Thursday, April 6 to “Sell” rating. H.C. Wainwright initiated the shares of SGYP in report on Thursday, October 1 with “Buy” rating. Cantor Fitzgerald initiated Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) rating on Thursday, June 1. Cantor Fitzgerald has “Buy” rating and $1100 target. The stock of Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) earned “Buy” rating by Rodman & Renshaw on Monday, May 9. The firm has “Buy” rating by Canaccord Genuity given on Thursday, January 25. The stock of Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) earned “Buy” rating by TH Capital on Thursday, October 29. The stock of Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) earned “Buy” rating by H.C. Wainwright on Thursday, August 10. The stock of Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) has “Buy” rating given on Monday, June 26 by BTIG Research. See Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) latest ratings:

25/01/2018 Broker: Canaccord Genuity Rating: Buy New Target: $13.0 Maintain
26/01/2018 Broker: BTIG Research Rating: Buy New Target: $7.0 Maintain
25/01/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $10.0 Maintain
22/01/2018 Broker: Oppenheimer Rating: Hold Maintain
08/01/2018 Broker: H.C. Wainwright Rating: Buy New Target: $7.0 Maintain
05/01/2018 Broker: Oppenheimer Old Rating: Outperform New Rating: Perform Old Target: $10 Downgrade
04/12/2017 Broker: H.C. Wainwright Rating: Buy New Target: $7.0 Maintain
21/11/2017 Broker: Cantor Fitzgerald Rating: Buy New Target: $10.0 Maintain
10/11/2017 Broker: Canaccord Genuity Rating: Buy New Target: $13.0 Maintain
09/11/2017 Broker: Cantor Fitzgerald Rating: Buy New Target: $10.0 Maintain

Balu Balakrishnan, the President and CEO of Power Integrations Inc, sold 3,116 shares of the company, with market value of approximately $240,536 USD, based on a stock price of $77.2 of a share. He also sold 9,488 shares with a total value $733,992 USD in the last 30 days. At the moment, Balu Balakrishnan possess a total of 368,577 shares or 1.24% of Power Integrations Inc’s market capitalization (total value of the shares outstanding). Dated January 30, 2018, this big sale by Balu Balakrishnan was revealed in the a public form which was filed together with the U.S. Security & Exchange Commission. It is obtainable for free here.

Power Integrations, Inc. designs, develops, and markets analog and mixed-signal integrated circuits, and other electronic components and circuitry used in high-voltage power conversion. The company has market cap of $2.22 billion. The firm offers a range of alternating current to direct current power conversion products that address power supply ranging from less than 1 watt of output to approximately 500 watts of output for mobile-device chargers, consumer appliances, utility meters, LCD monitors, main and standby power supplies for desktop computers and TVs, LED lamps, and other consumer and industrial applications. It has a 39.11 P/E ratio. It also provides high-voltage diodes; and high-voltage gate-driver products under the SCALE and SCALE-2 product-family names.

Investors sentiment decreased to 0.86 in Q3 2017. Its down 0.38, from 1.24 in 2017Q2. It worsened, as 28 investors sold Power Integrations, Inc. shares while 68 reduced holdings. 24 funds opened positions while 59 raised stakes. 28.33 million shares or 1.78% more from 27.83 million shares in 2017Q2 were reported. Robecosam Ag owns 195,000 shares for 1.11% of their portfolio. Tci Wealth Advisors Inc reported 0% stake. Moreover, Invesco Ltd has 0.03% invested in Power Integrations, Inc. (NASDAQ:POWI) for 1.04M shares. Wasatch Advisors, Utah-based fund reported 24,145 shares. The Nevada-based Whittier Of Nevada has invested 0% in Power Integrations, Inc. (NASDAQ:POWI). Credit Suisse Ag has invested 0% in Power Integrations, Inc. (NASDAQ:POWI). State Teachers Retirement Systems reported 0% stake. 46,203 are owned by Jpmorgan Chase Co. Texas Permanent School Fund has 0.02% invested in Power Integrations, Inc. (NASDAQ:POWI) for 21,725 shares. Disciplined Growth Mn has invested 1.86% of its portfolio in Power Integrations, Inc. (NASDAQ:POWI). Waddell And Reed Incorporated reported 693,097 shares. Victory Cap Management reported 2,112 shares. Hsbc Public Ltd Company holds 3,128 shares or 0% of its portfolio. 8,872 were accumulated by Ahl Prtn Llp. Impax Asset Management Ltd owns 839,787 shares for 1.88% of their portfolio.

Since August 22, 2017, it had 0 buys, and 5 selling transactions for $279,189 activity. $10,535 worth of Power Integrations, Inc. (NASDAQ:POWI) was sold by Bailey Doug on Monday, August 28. Shares for $71,224 were sold by Matthews David MH. $28,728 worth of stock was sold by Barsan Radu on Wednesday, August 30. The insider Petrakian Raja sold $156,518. Sutherland Ben also sold $12,184 worth of Power Integrations, Inc. (NASDAQ:POWI) shares.

The stock decreased 2.48% or $1.9 during the last trading session, reaching $74.7. About 183,995 shares traded or 66.52% up from the average. Power Integrations, Inc. (NASDAQ:POWI) has risen 41.25% since January 31, 2017 and is uptrending. It has outperformed by 24.55% the S&P500.

Among 6 analysts covering Power Integrations (NASDAQ:POWI), 3 have Buy rating, 0 Sell and 3 Hold. Therefore 50% are positive. Power Integrations has $88.0 highest and $50 lowest target. $72.20’s average target is -3.35% below currents $74.7 stock price. Power Integrations had 18 analyst reports since July 30, 2015 according to SRatingsIntel. The stock has “Buy” rating by Stifel Nicolaus on Friday, September 1. On Friday, November 13 the stock rating was maintained by Stifel Nicolaus with “Buy”. Deutsche Bank downgraded the shares of POWI in report on Tuesday, July 25 to “Hold” rating. Northland Capital maintained Power Integrations, Inc. (NASDAQ:POWI) on Thursday, October 29 with “Outperform” rating. The stock of Power Integrations, Inc. (NASDAQ:POWI) earned “Outperform” rating by Northland Capital on Thursday, July 30. The stock has “Buy” rating by Stifel Nicolaus on Friday, July 28. The rating was maintained by Stifel Nicolaus on Friday, December 29 with “Buy”. As per Thursday, July 30, the company rating was maintained by Stifel Nicolaus. As per Friday, June 30, the company rating was maintained by Stifel Nicolaus. The firm has “Buy” rating by Drexel Hamilton given on Friday, July 28.

Analysts await Power Integrations, Inc. (NASDAQ:POWI) to report earnings on February, 7. They expect $0.52 EPS, up 4.00% or $0.02 from last year’s $0.5 per share. POWI’s profit will be $15.45 million for 35.91 P/E if the $0.52 EPS becomes a reality. After $0.59 actual EPS reported by Power Integrations, Inc. for the previous quarter, Wall Street now forecasts -11.86% negative EPS growth.

Since August 7, 2017, it had 0 insider buys, and 1 sale for $98,972 activity. PAULSON & CO. INC. also sold $98,972 worth of Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) shares.

The stock increased 4.81% or $0.1 during the last trading session, reaching $2.18. About 8.82 million shares traded or 12.47% up from the average. Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) has risen 24.44% since January 31, 2017 and is uptrending. It has outperformed by 7.74% the S&P500.

Synergy Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat gastrointestinal diseases and disorders. The company has market cap of $537.72 million. The Company’s lead product is plecanatide, a novel uroguanylin analog that is traded under the TRULANCE name for the treatment of chronic idiopathic constipation and irritable bowel syndrome. It currently has negative earnings. The firm also develops dolcanatide to treat mild-to-moderate ulcerative colitis.

Investors sentiment increased to 1.9 in Q3 2017. Its up 0.41, from 1.49 in 2017Q2. It increased, as 16 investors sold Synergy Pharmaceuticals Inc. shares while 23 reduced holdings. 21 funds opened positions while 53 raised stakes. 147.06 million shares or 7.33% less from 158.68 million shares in 2017Q2 were reported. Goldman Sachs holds 3.32M shares or 0% of its portfolio. California State Teachers Retirement Sys, California-based fund reported 365,145 shares. Deutsche Natl Bank Ag holds 0% or 2.38M shares. Virtu Fincl Ltd Llc holds 0% or 28,936 shares. Hsbc Public Ltd Co has invested 0% in Synergy Pharmaceuticals Inc. (NASDAQ:SGYP). Ameritas Inv holds 0% of its portfolio in Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) for 19,906 shares. Metropolitan Life Insurance Company reported 0% in Synergy Pharmaceuticals Inc. (NASDAQ:SGYP). Kingdon Cap Mgmt Ltd Liability Corp reported 0.15% of its portfolio in Synergy Pharmaceuticals Inc. (NASDAQ:SGYP). Cubist Systematic Strategies Ltd Liability Company holds 0% or 21,381 shares in its portfolio. First Tru Advisors L P owns 13,210 shares for 0% of their portfolio. Jane Street Grp Inc Limited Liability Corporation invested in 196,976 shares or 0% of the stock. Equitec Specialists Ltd Liability holds 0% or 3,000 shares. Art Advisors Limited Liability Company holds 0.07% of its portfolio in Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) for 479,300 shares. American Grp Incorporated Inc stated it has 152,047 shares. 34,205 were accumulated by Creative Planning.

Free Email Newsletter

Enter your email address below to get the latest news and analysts’ ratings for your stocks with our free daily email newsletter: